Every 8-K that Century Therapeutics, Inc. (IPSC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IPSC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IPSC filings page.
Century Therapeutics, Inc. (IPSC) expanded its Board of Directors from six to seven members and appointed Joseph Truitt as a Class I director effective September 9, 2026, with a term running to the 2028 annual stockholders’ meeting. Truitt will also serve on the Compensation Committee and has been deemed an independent director under Nasdaq rules.
For his board service, Truitt will receive an initial option to purchase 148,000 shares of common stock vesting in equal monthly installments over 36 months, plus an annual cash retainer of $40,000, under Century’s existing non‑employee director compensation program. Century highlighted continued progress of its pipeline, stating that CNTY‑813 remains on track for an IND submission in the fourth quarter of 2026 and that CNTY‑308 is anticipated to enter the clinic in 2026, both leveraging its Allo‑Evasion™ 5.0 platform.
Century Therapeutics, Inc. reported second quarter 2026 results and pipeline updates. The company is advancing CNTY-813, an iPSC-derived cell therapy for type 1 diabetes, having held a pre-IND meeting with the FDA that yielded alignment on its nonclinical data package, manufacturing strategy, and proposed Phase 1/2 trial design. Phase 1 manufacturing has been established with consistent product quality, and an IND filing for CNTY-813 remains on track for the fourth quarter of 2026. CNTY-308 is planned to enter the clinic in 2026.
For the quarter ended June 30, 2026, Century reported no collaboration revenue, compared with $109.2 million in collaboration revenue in the first half of 2025. The company recorded a net loss of $34.6 million for the quarter and $56.2 million for the first half of 2026, versus net income of $44.0 million in the first half of 2025. Results include an $11.1 million loss on lease component termination. Research and development expenses declined to $19.6 million from $26.9 million in the prior-year quarter, and general and administrative expenses fell to $5.8 million from $7.8 million. As of June 30, 2026, cash and cash equivalents were $49.6 million, with short-term investments of $70.1 million and long-term investments of $77.5 million.
Century Therapeutics, Inc. updated the employment terms for its Chief Scientific Officer, Chad Cowan, Ph.D., through an Amended and Restated Employment Agreement. Under this new arrangement, he will continue serving as Chief Scientific Officer on a part-time basis with a reduced annual salary of $296,150.
Dr. Cowan will remain eligible for an annual performance-based target bonus, calculated on a pro-rated basis to reflect his part-time role. If his employment ends through termination by the company or his resignation, he will receive all accrued and unpaid base salary through his final date of employment.
Century Therapeutics, Inc. increased the number of authorized shares of its common stock from 300,000,000 to 450,000,000 through a Certificate of Amendment that became effective on June 12, 2026. Stockholders approved this Authorized Shares Amendment at the company’s 2026 Annual Meeting.
At the same meeting, stockholders elected Alessandro Riva, M.D. and Han Lee, Ph.D., M.B.A. as Class II directors, each to serve until the 2029 Annual Meeting. They also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the 2026 fiscal year and approved an adjournment proposal, although an adjournment was not needed.
Century Therapeutics filed an 8-K after presenting new preclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at the American Diabetes Association 2026 Scientific Sessions. CNTY-813 uses the company’s Allo-Evasion™ 5.0 immune evasion technology.
In diabetic mouse models, CNTY-813 islet cells rapidly restored normal blood sugar and maintained glucose control for more than eight months, with glucose normalization within 60 minutes on tolerance testing. Safety data showed stable graft morphology, no abnormal outgrowth, and no tumorigenesis across over 140 mice infused with one billion cells.
The company also reported strong in vitro and in vivo immune protection, including preserved C-peptide secretion and glucose tolerance in a humanized allogeneic rejection model, and consistent product quality from its Phase 1 manufacturing process. Century is targeting an IND submission for CNTY-813 in the fourth quarter of 2026 and anticipates initial clinical data in the second half of 2027.
Century Therapeutics reported first quarter 2026 results showing no collaboration revenue compared with $109,164k a year earlier, leading to a net loss. Operating expenses fell to $23,684k from $34,988k as research and development and general and administrative costs both declined.
The company posted a net loss of $21,645k, versus net income of $76,560k in the prior-year quarter, with basic and diluted net loss per share of $0.11 compared with earnings of $0.89. Cash and cash equivalents were $51,048k, and total assets rose to $326,553k with stockholders' equity of $264,744k.
Century Therapeutics, Inc. filed a current report describing updates to its shelf registration and at-the-market equity program. A new Form S-3 shelf registration statement became effective on January 9, 2026, replacing the prior shelf. The company also filed a new prospectus supplement dated March 26, 2026 for its existing at-the-market equity offering program with Cowen and Company, LLC, predecessor to TD Securities (USA) LLC, as sales agent under a July 1, 2022 Sales Agreement. Under this program, the company may issue and sell shares of common stock having an aggregate offering price of up to $150,000,000. It has already sold shares with an aggregate offering price of $18,380,259, leaving up to $131,619,741 of common stock available for future sale under the program.
Century Therapeutics reported sharply improved 2025 results while remaining loss-making. Collaboration revenue rose to $109.2M for the year ended December 31, 2025, up from $6.6M in 2024, reflecting a major step-up in partnered activity.
Total operating expenses declined to $126.4M from $144.7M, driven by lower research and development and general and administrative costs, partly offset by $6.8M in asset impairment charges. Net loss narrowed to $9.6M (or $0.14 per share) from $126.6M (or $1.61 per share). As of December 31, 2025, the company held $61.9M in cash and cash equivalents and $55.3M in short-term investments, with total assets of $223.7M and stockholders’ equity of $158.9M. Management highlighted progress on CNTY-813 for type 1 diabetes, targeting an IND as early as the fourth quarter of 2026 and initial clinical data in the second half of 2027.
Century Therapeutics, Inc. held a special stockholder meeting where investors approved an amendment to its charter that would allow a reverse stock split of its common stock at a ratio between 1-for-5 and 1-for-30, at the discretion of the board. The proposal received 55,089,478 votes for, 5,361,020 against, and 27,055 abstentions, indicating strong support for the potential split. On the same day, the company received notice from the Nasdaq Stock Market that it had regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share. Because the company is now in compliance with all continued listing standards, it does not intend to implement the reverse stock split that stockholders approved.
Century Therapeutics, Inc. filed a current report to notify investors that it has updated its corporate slide presentation. The revised investor presentation, dated January 12, 2026, is attached as Exhibit 99.1 and may be used by company representatives in meetings with investors from time to time.
The company states that the information in this report and the attached presentation is being furnished rather than filed under the securities laws, meaning it is not automatically incorporated into other securities filings unless specifically referenced.
Century Therapeutics entered into a private placement with institutional investors to raise approximately $135.0 million in gross proceeds. The company agreed to sell 92,030,595 shares of common stock and/or pre-funded warrants for 25,360,704 shares, plus warrants for 58,695,648 shares, at a purchase price of $1.15 per share and accompanying warrant, or $1.1499 per pre-funded warrant and accompanying warrant. Pre-funded warrants are exercisable immediately at $0.0001 per share and do not expire, while common warrants are exercisable immediately at $2.60 (or $2.599 for a pre-funded warrant) and expire on the earlier of 30 days after public announcement of initial Phase 1 data for CNTY-813 or three years after closing. The company plans to use the net proceeds primarily to fund development of CNTY-813 and for working capital and general corporate purposes.
Century Therapeutics, Inc. reported that board member Carlo Rizzuto, Ph.D., has resigned from its board of directors, effective December 18, 2025. The company states that Dr. Rizzuto’s decision to step down was not due to any disagreement with the company regarding its operations, policies, or practices. Century Therapeutics publicly thanked Dr. Rizzuto for his distinguished service and contributions to the company.
Century Therapeutics, Inc. (IPSC) furnished materials related to its latest quarter and pipeline. The company provided an earnings press release for the quarter ended September 30, 2025, and an updated investor presentation. It also announced its first Type 1 diabetes program, CNTY-813.
The earnings release (Exhibit 99.1), investor presentation (Exhibit 99.2), and CNTY-813 press release (Exhibit 99.3) were furnished on November 13, 2025 and are not deemed “filed” under the Exchange Act.
Century Therapeutics, Inc. received a deficiency letter from Nasdaq after its closing bid price fell below the $1.00 minimum over the last 30 consecutive business days, triggering a 180-day compliance period that ran to August 26, 2025. Nasdaq determined the company otherwise met market value and initial listing requirements for The Nasdaq Capital Market and accepted the company's plan to cure the deficiency, including a possible reverse stock split. On August 27, 2025 Nasdaq approved Century's transfer from The Nasdaq Global Select Market to The Nasdaq Capital Market and the company's common stock continues to trade under the symbol IPSC. The filing notes the transfer became effective at the opening of business on August 27, 2025, although one date in the text appears truncated.